Slides
Page 1
Corporate Webcast ASH Abstract Update November 4, 2026
Page 2
Agenda 02 03 ASH Abstract HighlightsMohamed Zaki Chief Medical Officer Financial UpdatePepe Carmona Chief Financial Officer 01 IntroductionAmeet Mallik Chief Executive Officer 04 Q&A
Page 3
3ADC Therapeutics | Forward-Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or ADC Therapeutics or any officer, director, employee, agent or advisor of ADC Therapeutics. This presentation does not purport to be all‐inclusive or to contain all of the information you may desire. Information provided in this presentation and any accompanying oral presentation speak only as of the date hereof. This presentation contains forward -looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward -looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predi ct", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward -looking statements contain these identifying words. Forward -looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the adequacy of the LOTIS -5 clinical trial data to support full regulatory approval and our ability to maintain accelerated approval in the United States and foreign jurisdictions for our product; our ability to identify and execute on potential regulatory and compendia p athways; the timing, content and outcome of meetings with and feedback or other communications provided by regulatory authorities including U.S. FDA including our ability to adequately address the serious concerns related to the LOTIS-5 trial results raised by the FDA at the recent pre -sBLA submission meeting; the timing, submission and outcome of an sBLA related to LOTIS -5 and potential approval; the actual and perceived benefit -risk profile for ZYNLONTA as studied in the LOTIS -5 trial; the assessment of the data from LOTIS -5 study, including additional analyses of outcomes observed for safety, efficacy and within key geographic regions and across certain patient sub -populations; the path for full regulatory approval for ZYNLONTA in the United States and foreign jurisdictions and into earlier lines of therapy; the timing and publication of the full LOTIS -7 trial data and potential NCCN compendia inclusion; future regulatory strategy for a Phase 3 trial for the combination of ZYNLONTA plus glofitamab and the timing and results of such trial; the timing and publication of the investigator -initiated trials studying FL and MZL and the po tential NCNN compendia inclusion and regulatory strategy and the future opportunity; the impact, if any, from the various abstracts and presentations at ASH; whether Tanabe’s marketing authorization application filed with Japan’s Ministry of Health for ZYNLONTA will be accepted, the timing and potential approval of the marketing authorization application for ZYNLONTA in Japan, the timing and payment of future regulatory and commercial milestones relate d to Japan, Nippon Shinyaku ability to successfully commercialize ZYNLONTA in Japan and the amount of future revenue in Japan and related payments to ADCT; our expected revenue growth in 2027 and the Company's ability to sus tain or grow ZYNLONTA revenue in the future; our expected cash runway into 2029; changes in our regulatory and commercial strategy; the ability of our partners to commercialize ZYNLONTA in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain or maintain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's future clinical trials and investigator initiated trials; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Com pany's indebtedness, including HealthCare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the va rious agreements and repay such indebtedness and the significant cash required to service such indebtedness; our ability to effect the proposed amendments to the HCR agreement and the loan agreement; the Company's abilit y to obtain financial and other resources for its research, development, clinical, and commercial activities; uncertainties related to a potential change in domicile from Switzerland to Delaware, including the outcome of ta x analyses associated with such redomiciliation , the receipt of requisite shareholder approval, and the ability to complete the redomiciliation on the anticipated terms and timeline, if at all; and the uncertainties of international trade policies, including tariffs, s anctions, trade barriers and most favored nation drug pricing and the potential impact they may have on our business, financial condition, and results of operations. Additional information concer ning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10 -K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward -looking statements. The Company cautions investor s not to place undue reliance on the forward -looking statements contained in this document. This presentation includes preliminary revenue and cash and cash equivalents figures, which reflect the Company’s estimated f inancial results. In preparing this information, management made a number of complex and subjective judgments and estimates about the appropriateness of certain reported amounts and disclosures. The Company’s actual financial results as of and for the three and nine months ended September 30, 2026 have not yet been finalized by management. The preliminary financial information is not a comprehensive statement of all financial results. Sub sequent information or events may lead to material differences between the preliminary financial results and those reported in the Company’s subsequent SEC filings. Accordingly, investors should not place undue reliance on these p reliminary financial results. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our m anagement. No assurance can be given that such future results will be achieved. Such forward - looking statements contained in this presentation speak only as of the date of this presentation. The Company expressly discl aim any obligation or undertaking to update these forward -looking statements contained in this presentation to reflect any change in our expectations or any change in events, conditions, or circumstances on which such st atements are based unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward -looking statements. Certain information contained in this presentation relates to or is based on studies, publications, surveys, and other data d erived from third-party sources and our own internal estimates and research. While we believe these third - party sources to be reliable as of the date of this presentation, we have not independently verified, and we make no represen tation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third - party sources. In addition, all of the market data included in this presentation involve a number of assumptions and limitati ons, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, although we believe our own internal research is reliable, such research has not been verified by any independent source. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sales of securities in any state jurisdiction in which such offer, solicitation of sale would be unlawful prior to registration of qualification under the securities laws of any such state or jurisdiction.
Page 4
Value Drivers Supported by a Strong Balance Sheet Approved product 2L+ DLBCL LOTIS - 7: ZYNLONTA plus glofitamab MZL IIT: ZYNLONTA monotherapy Strong balance sheet provides broader strategic optionality
Page 5
Key Business Updates Net product revenues from sales of ZYNLONTA expected to be $21 million for the third quarter ended September 30, 2026 Commercial Performance ASH Abstracts ASH Data Highlights Breadth of ZYNLONTA® Clinical Program with 5 oral presentations: Phase 1b LOTIS-7 abstract data demonstrating potentially best-in-class efficacy with an 88.7% ORR and 75.3% CR across the 97 efficacy-evaluable patients Robust and durable 93% ORR and 74.4% CRR seen with ZYNLONTA in Phase 2b marginal zone lymphoma IIT abstract Additional oral presentations to feature full Phase 3 LOTIS-5 results and investigator-initiated studies in mantle cell lymphoma and Waldenström macroglobulinemia Corporate Update $86.6 Million Private Placement announced, with participation from new and existing investors HealthCare Royalty financing agreement amended, removing change-of-control payment Senior secure loan refinanced, decreasing principal to $50M with bullet payment in August 2029 and no minimum liquidity Expected cash runway into 2029 with cash and cash equivalents of $189.2 million as of September 30, 2026 and proforma cash post-refinancing of $196 million
Page 6
6ADC Therapeutics | *Efficacy evaluable includes treated population who met all eligibility criteria and underwent >/= 1 disease assessment or experienced clinical progression prior to first scan +Includes 5 patients who received CAR -T or SCT while in CR NALT = new anti-lymphoma treatment Data cutoff: 15Jun2026 Note: Data extracted from live clinical database as reported by investigators. Data is subject to change. LOTIS-7 Phase 1b Trial: Response r/r Large B-Cell Lymphoma efficacy evaluable population* at ZYNLONTA 150 µg/kg starting dose in Parts 1 and 2 as of data cutoff of June 15, 2026 Of the 73 patients+ who achieved CR, 62 (84.9%) remained in CR DoCR rate at 6 and 12 months were 81.9% and 79.0% respectively Median follow-up 10.35 months with median DoR, DoCR and PFS not reached Deep and durable complete responses All Efficacy Evaluable Patients (n= 97) PR: 13.4% (n=13) ORR: 88.7% (n=86) CR: 75.3% (n=73) PD: 9.3% (n=9)SD: 2.1% (n=2) 28 patients converted from SD (1) or PR (27) to CR over time • In patients with primary refractory disease (n=54): an ORR of 78.4% and CRR of 64.7% were observed • Among patients with prior CAR-T exposure (n=28): an ORR of 74.1% and CRR of 63.0% were observed • In an exploratory MRD analysis of 12 patients achieving CR: 50% achieved undetectable MRD ( uMRD) as early as C2D1 with 11 of the 12 uMRD at EoT Other notable efficacy results
Page 7
7ADC Therapeutics | LOTIS-7: Continues to Demonstrate Manageable Safety Profile Combination generally well tolerated with a manageable safety profile Types of TEAEs observed generally consistent with the known safety profiles of each drug separately Low rates and grades of CRS and ICANS at the selected ZYNLONTA 150µg/kg* starting dose *Reduce ZYNLONTA to 75 ug/kg at C3 a Includes adverse events reported in ≥5% of patients (rounded); i.e., all events with an incidence ≥4.5%. b As per Investigator reported adverse events, based on AESI group term and MedDRA preferred term c AESIs (Adverse Events of Special Interest, specific to loncastuximab, not glofitamab) d ASTCT grading used for CRS and ICANS r/r Large B-Cell Lymphoma all ZYNLONTA Treated Population* (N=103) at ZYNLONTA 150 µg/kg starting dose in Parts 1 and 2, as of Data Cutoff of June 15, 2026 The most common (≥30%) any grade TEAEs were: neutropenia (45.6%), fatigue (36.9%), gamma - glutamyltransferase (GGT) increased (35.9%), thrombocytopenia (32.0%), maculopapular rash (32.0%), and cytokine release syndrome (CRS) (32.0%) The most common (≥10%) grade ≥3 TEAEs were: neutropenia (36.9%), GGT increased (20.4%), anemia (10.7%), and thrombocytopenia (10.7%) The rate of ICANS was: 4.9% (any grade) with no grade ≥3 ICANS events Most CRS events were: low grade (grade 1, 25.2%; grade 2, 5.8%), and one grade 3 CRS event was reported There were 3 grade 5 TEAEs, one due to sepsis and two due to capillary leak syndrome
Page 8
8ADC Therapeutics | ZYNLONTA in 2L+MZL: Phase 2 IIT Updated Efficacy Overview Source: ASH Abstract submitted on Aug 4, 2026 by Dr. I. Lossos, University of Miami (as of July 1, 2026) Note: N=43 patients who were efficacy evaluable , N=47 patients enrolled (intent to treat) All Efficacy Evaluable Patients (n= 43) PR: 11.6% (n=5) Best ORR: 93% (n=40) CR: 74.4% (n=32) SD: 7.0% (n=3) As of July 1, 2026, the best ORR was 93% (n=40) with CR rate of 74.4% (n=32) With a median follow up of 23.2 months (95%CI: 12.5-28.7), all but 1 patient were alive with a 2-year PFS of 90.8% (95%CI: 67.4-97.7) Duration of response (CR/PR) at 24 months was 90.9% (95%CI: 67.7-97.7) Updated results as of data cutoff of July 1, 2026
Page 9
9ADC Therapeutics | ZYNLONTA in 2L+ MZL: Phase 2 IIT Updated Safety Overview Updated data as of July 1, 2026 cutoff suggest manageable safety generally consistent with known profile of ZYNLONTA Adverse events were most commonly grade 1 or 2 Most common G1-2 events were abnormal LFTs (28), rash (19), nausea (16), fatigue (15), anemia (14), leg edema (12) and pleural effusion (5) Grade 3 AEs (n=36) were observed in 23 patients Most common G3 events included elevation of ALT (4), AST (1), alkaline phosphatase (3), anemia (5) and lung infections (5) Grade 4 (n=5) were observed in 5 patients G4 events included neutropenia (2), thrombocytopenia (2), and hyponatremia (1) Source: ASH Abstract submitted on Aug 4, 2026 by Dr. I. Lossos, University of Miami (as of July 1, 2026) Note: N=43 patients who were efficacy evaluable , N=47 patients enrolled (intent to treat)
Page 10
10ADC Therapeutics | LOTIS-5: Confirmatory Phase 3 Trial Met Primary Endpoint, However, Grade 5 Safety Imbalance Observed Between Arms Event-free rate (95% CI) ZYNLONTA + rituximab, % R-GemOx,% 6M 50.4 (43.0, 57.3) 38.9 (31.4, 46.3) 12M 29.6 (22.9, 36.5) 23.7 (17.2, 30.8) 18M 25.1 (18.7, 32.0) 14.7 (9.2, 21.5) 24M 23.2 (16.9, 30.1) 9.5 (4.8, 16.2) ZYNLONTA+R: R-GemOx: Censored: Patie nts at ri sk: ZY NLONTA+R ZYNLONTA+R: 6.14 (4.99, 8.11) R-GemOx: 4.73 (2.83, 5.55) Hazard Ratio (95% CI): 0.73 (0.57, 0.92) Two-sided p-value: 0.0084 Median PFS, months (95% CI) Trial Results Met primary endpoint of PFS with statistical significance Efficacy → Randomized, open-label, two-arm Phase 3 confirmatory trial evaluating ZYNLONTA + rituximab versus R-GemOx in 2L+ DLBCL → Study met primary PFS endpoint with statistical significance (HR=0.73, two-sided p-value 0.008) and resulted in a higher CR rate with ZYNLONTA + rituximab vs. R-GemOx (~40% vs ~27%) Safety → Overall TEAE and Grade ≥3 TEAE rates were similar between arms → Grade 5 TEAEs were higher in the ZYNLONTA + rituximab arm (13.2% vs. 4.6%), driven primarily by infection-related events – Infection prophylaxis not required and used at the investigator’s discretion – Prophylaxis less frequently used in the ZYNLONTA + rituximab arm than in the R-GemOx arm (57.8% vs. 77.2%) – Consistent with this difference, Grade ≥3 infections (24.5% vs. 15.7%) and Grade 5 infections (7.4% vs. 2.5%) were more frequent in the ZYNLONTA + rituximab arm – Meaningful decrease in Grade 5 events observed in the ZYNLONTA + rituximab arm in patients receiving prophylaxis → Longer treatment / TEAE observation time with ZYNLONTA + rituximab also contributed to higher observed event rates Next Steps → FDA cited concerns regarding the benefit-risk or verification of clinical benefit for this combination → ADC Therapeutics expects to provide an update on its regulatory strategy and timing in the future
Page 11
11ADC Therapeutics | R/R WM | R/R MCL Initial Data Show Promising ZYNLONTA Activity as Consolidation Following Traditional Chemotherapy in r/r Mantle Cell Lymphoma Oral presentation announced for Investigator-initiated Phase II trial at ASH 2026 COLUMN (N=49) Fondazione Italiana Linfomi (FIL) - Data cutoff July 1, 2026 Primary endpoint met : 12-mo PFS 70% (90% CI 54 –81); 24-mo PFS 49% Lonca consolidation deepened responses : CR rate rose from 46.9% to 71.4% Manageable toxicity , mainly hematologic; Gr 3 –4 cytopenias lower in consolidation than induction Regimen 1–2 cycles R-BAC, then (if patients achieved >SD) received 4 Lonca infusions q3w (150 µg/kg ×2, 75 µg/kg ×2) Patients Median age 69; median 3 prior lines; 100% prior BTKi; 14.3% prior CAR -T; 49 enrolled, of which 42 proceeded to Lonca after R -BAC Efficacy 12-mo PFS 70% (primary endpoint met); ORR 81.6% post R-BAC; CR 46.9% → 71.4% post Lonca Survival 12-mo OS 74%; 24 -mo OS 61%; median f/u 22 mo Gr ≥3 AEs (induction / consolidation) Neutropenia 55.8% / 32.4%; thrombocytopenia 48.9% / 13.5%; infections 9.3% / 8.1% Lonca discontinuation due to AEs 6/42 (14.3%) in consolidation ( 3 neutropenia, 1 thrombocytopenia, 1 skin, 1 hepatic) ~4,000 2L+ drug treated patients per year in the US 1L MCL treatment is stratified by disease risk characteristics and traditional chemo regimens and BTKi combinations are recommended BTKi mono-therapies are standard of care in 2L+ MCL After BTKi failure, treatment options include traditional chemo combinations, CAR-T cell therapies, and bispecific antibodies R-BAC is primarily considered a salvage regimen with limited durability Unmet need remains for treatment options that offer durable responses to patients who progress after treatment with BTKis Overview of Mantle Cell Lymphoma % Acalab rutinib80% 2L+ MCL FDA Approved regimens 0 - 80 - 60 - 40 - 20 - 100 - ORR Zanubrutinib84% Acalab rutinib40% 0 - 80 - 60 - 40 - 20 - 100 - CR Zanubrutinib59% Acalabrutinib USPI, ACE -LY-004 (r/r MCL n=124); Brexucabtagene autoleucel USPI, ZUMA -2 Cohort 1 (r/r MCL treated n=60); Lisocabtagene maraleucel USPI, TRANSCEND -MCL (r/r MCL treated n=68); Pirtobrutinib USPI, BRUIN (n=120); Sonrotoclax USPI, BGB -11417 -201 (r/r MCL n=103) ; Zanubrutinib U SPI, BGB -3111-206 (n=201, r/r MCL n=86) Liso-cel85% Pirtobrutinib13% Brexu-cel62% Sonrotoclax52% Sonrotoclax16% Brexu-cel87% Liso-cel68% Pirtobrutinib50%
Page 12
12ADC Therapeutics | R/R WM | R/R MCL WM-NET1 (N=20) High ORR in heavily pre -treated patients (ORR 90% and VGPR/CR 60%) (median 4 prior therapies; 67% TP53 alterations) Rapid time to response : median time to major response of 2 months Time-limited therapy with manageable safety ; reversible cytopenias most common; no TLS, IgM flare, or infusion reactions Regimen Lonca 150 µg/kg C1–2, 75 µg/kg C3–6 (28-day cycles) + dexamethasone (day before, of and after Lonca) Patients Median age 72; 68% CXCR4 mutated; 67% TP53 altered; median prior therapies: 4 Efficacy VGPR/CR 60% (12/20; primary endpoint met, ≥6 required); ORR 90%; CR 10%, VGPR 50%, PR 20% (MRR 80%) Survival 18-mo PFS 57%; 18-mo OS 77%; median f/u 19 mo Gr ≥3 AEs Neutropenia 70%; anemia 50%; thrombocytopenia 35%; infections 30% Treatment discontinuation 6/20 (30%) Due to: GGT elevation n=2, cytopenias n=2, rash n=1, patient decision n=1 Waldenström macroglobulinemia (WM) is a rare, indolent, incurable lymphoma 1L WM treatment decision making is stratified by disease risk characteristics and standard-of-care includes BTKis (Zanubrutinib) and traditional chemotherapy combinations (Benda-Ritux) Patients often require multiple lines of therapy, with progressively shorter durations of disease control after each subsequent treatment Unmet need remains for time-limited treatment options that provide deep responses in high-risk patients Overview of Waldenström Macroglobulinemia % Pirtobrutinib73% 2L+ WM regimens 0 - 80 - 60 - 40 - 20 - 100 - MRR Zanubrutinib78% Ibrutinib+/-R76% Pirtobrutinib27% 0 - 80 - 60 - 40 - 20 - 100 - CR + VGPR Zanubrutinib28% Ibrutinib+/-R30% Benda-R81% Benda-R39% Overall Response Rate (ORR): Complete Response (CR) + Very Good Partial Response (VGPR ) + Partial Response (PR) + Minor Response (MR). Major Response Rate (MR R): CR + VGPR + PR. Acalabrutinib Owen et al., Blood Adv (2026) (r/r n=92). Benda -R Paludo et al., Ann Hematol (2018 – retrospective) (n=160, r/r WM BR n=43). Ibrutinib USPI, INN OVATE (n=150, 55% r/r WM). Pirtobrutinib BRUIN, 5 -year follow -up (r/r WM n=80). Zanubrutinib USPI, ASPEN (n=201, 82% r/r WM). FDA-approved NCCN -only KEY Updated Data Continue to Show Promising ZYNLONTA Activity in High-risk and Heavily Pre-treated r/r Waldenström Macroglobulinemia Oral presentation announced for Investigator-initiated Phase II trial at ASH 2026 Dana-Farber, Mass General, Mayo Clinic, Fred Hutch – April 2026 Acalab rutinib82% Acalab rutinib44% Major Response Rate Complete Response + Very Good Partial Response ZYNLONTA is currently included in NCCN guidelines for 2L+ WM as category 2A, “useful in certain circumstances”
Page 13
Date Presentation Time Title Type Saturday, December 12 2:45 PM - 3:00 PM Loncastuximab tesirine consolidation after short-course R-BAC induction in BTKi-exposed R/R mantle cell lymphoma : Primary endpoint analysis from the phase II column trial from fondazione italiana linfomi (FIL) Oral #238 Sunday, December 13 12:00 PM - 12:15 PM Updated Results from LOTIS-7: A Phase 1b Study Evaluating the Safety and Efficacy of Loncastuximab Tesirine in Combination With Glofitamab in Patients With Relapsed or Refractory Large B -Cell Lymphoma Oral #619 Monday, December 14 11:00 AM - 11:15 AM Phase II trial of loncastuximab tesirine (WM-NET1 trial) in patients with relapsed/refractory and high -risk Waldenström macroglobulinemia Oral #783 11:15 AM - 11:30 AM Fixed-duration loncastuximab tesirine induces a high rate of complete and durable responses in patients with relapsed/refractory marginal zone lymphoma - report of a multicenter phase II study Oral #784 3:00 PM - 3:15 PM Results from the Phase 3 LOTIS-5 Study: Efficacy and Safety of Loncastuximab Tesirine Plus Rituximab vs Immunochemotherapy in Patients with Relapsed or Refractory DLBCL Oral #920 ZYNLONTA Data Included in 5 Orals at ASH 2026 Provides insights into potential use across multiple B-cell lymphomas and rare diseases
Page 14
14 CORPORATE → $86.6M Private Placement announced extending expected cash runway into 2029 – Included new (Bain Capital Life Sciences), existing (Redmile, TCGX, Nantahala Capital) investors → HealthCare Royalty financing agreement amended, fully removing $150M change-of-control payment – Reduced the exercise price of ~9.8M warrants from $3.8130 to $0.10 per share → Senior secured loan refinanced, decreasing principal to $50M with bullet payment in August 2029 and no minimum liquidity – Revenue covenant reduced to flat $65M versus $70M in 2026 and up to $94M in 2029 – Reduced the exercise price of ~527K warrants from $8.30 to $1.00 per share → Tanabe Pharma filed for Japanese approval of ZYNLONTA and entered into exclusive sublicensing agreement with Nippon Shinyaku – Supports anticipated regulatory and commercial milestones for ADC Therapeutics Comprehensive Strategic Financial Restructuring Strengthened balance sheet, reduced leverage, and increased strategic optionality
Page 15
15 Selected Financial Data (Preliminary) For the quarter ended September 30, 2026 Expected Net Product Revenue – Q3 Expected Cash Balance All figures reflect in USD M 16 21 2025 2026 +5 51 60 2025 2026 +8 QTD YTD Increase in Product Revenues, net from sales of ZYNLONTA in the quarter and year-to-date periods were primarily attributable to an increase in sales volume (1) Cash used in Q3 includes one-time severance and retention payments of $13M (2) Pro forma cash giving effect to the estimated net cash proceeds from the PIPE of $76M ($86.6M PIPE transaction value less warrant par value of $4.6M & offering fees $5.7M), and the partial principal prepayment of $68.5M on the senior secured term loan as well as exit fees / interest $1.5M, which closed on October 22, 2026. 219 189 196 Q2 2026 Q3 2026 Adjusted Cash Balance -30 (1) +7 (2)
Page 16
16ADC Therapeutics | Expanding the ZYNLONTA Franchise Advancing Into Earlier-Line DLBCL and Indolent Lymphomas Indication Regimen (Target) Trial Phase of Development Status / Next Milestone 3L+ DLBCL ZYNLONTA Monotherapy LOTIS-2 Mkt FDA accelerated approval in 2021 Commercially available 2L+ DLBCL ZYNLONTA + rituximab (CD20) LOTIS-5 Ph3 P3 confirmatory trial; met primary endpoint Oral presentation at ASH 2026 Regulatory pathway under evaluation following FDA benefit-risk feedback 2L+ DLBCL ZYNLONTA + glofitamab (CD3xCD20) LOTIS-7 Ph1b Oral presentation at ASH 2026 P3 design under evaluation Compendia submission planned Q1 2027 Phase 2 2L+ Follicular Lymphoma ZYNLONTA + rituximab (CD20) Phase 2 IIT Updated data anticipated in Q2 2027Ph2 2L+ Marginal Zone Lymphoma ZYNLONTA Monotherapy Phase 2 IIT Oral presentation at ASH 2026 BTD submission planned H1 2027 Compendia submission planned H2 2027 Ph2 • Rituximab (Rituxan) is a CD20-targeting monoclonal antibody marketed by Roche • Glofitamab (Columvi) is a CD20 x CD3 bispecific antibody marketed by Roche Sources: LOTIS-2 study USPI, LOTIS-5 topline results (response rate by IRC), LOTIS-7 data as of November 2025 data cut-off; MZL data as of February 2025; FL data as of September 2025 Response Rates ORR: 48% CR: 25% ORR: 58% CR: 40% ORR: 90% CR: 78% ORR: 98% CR: 84% ORR: 85% CR: 69%
Page 17
17ADC Therapeutics | Key Near-Term Anticipated Milestones FDA engagement regarding ZYNLONTA + glofitamab Phase 3 study design Q4 2026 LOTIS-7 Ph1b & MZL IIT updated data ASH presentations 1H 2027 LOTIS-7 compendia inclusion MZL IIT Breakthrough Designation submission 2H 2027 Ph3 initiation for 2L+ DLBCL ZYNLONTA + glofitamab MZL IIT compendia inclusion
Page 18
Thank You